Biocon Limited is India's premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Overview:
Established in 1978 by Ms Kiran Mazumdar-Shaw, Biocon is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases to provide access to affordable treatment to patients across the global.
Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR® , for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India.
With a risk balanced business model comprising small molecules, novel molecules, biosimilars, branded formulations and research services, Biocon has evolved into an emerging global enterprise serving its partners and customers in over 70 countries
Shared 1 month ago
2.3K views
Shared 1 month ago
2.4K views
Shared 5 months ago
60 views
Shared 9 months ago
696 views
Shared 1 year ago
556 views
Shared 1 year ago
943 views
Shared 1 year ago
84 views
Shared 1 year ago
762 views
Shared 1 year ago
83 views
Shared 1 year ago
5K views
Shared 1 year ago
618 views
Shared 2 years ago
1.2K views
Shared 2 years ago
1.5K views
Shared 2 years ago
1.8K views
Shared 2 years ago
1K views
Shared 3 years ago
661 views
Kiran Mazumdar - Shaw,Executive Chairperson, Biocon & Biocon Biologics speaking on Q4 & FY23 Results
Shared 3 years ago
700 views
Shared 3 years ago
249 views
Shared 3 years ago
897 views
Shared 3 years ago
349 views
Shared 3 years ago
958 views
Shared 3 years ago
5.6K views
Shared 4 years ago
7.2K views
Shared 4 years ago
300 views
Shared 4 years ago
1.5K views
Shared 4 years ago
2.4K views
Shared 4 years ago
592 views
Shared 4 years ago
361 views